Little Green Pharma Ltd has released a press release.
Ethics approval for CBD Phase III clinical trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Little Green Pharma Ltd. on 6ix
Story so far
Earlier from Little Green Pharma
- LGP significantly expands flower portfolio
- Prospectus
- Share Purchase Plan open to eligible shareholders
- Update Four 20 Pharma and French trial extension
- LGP announces $4 million placement and $2 million SPP
Later from Little Green Pharma
- Second exclusive supply agreement with Cannamedical
- Share Purchase Plan offer extended to 16 January 2023
- Psilocybin and MDMA down-scheduled
- Ethics approval granted for psilocybin clinical trial
- Reset Mind Sciences and HIF enter Strategic Alliance
Follow Little Green Pharma into a list and get an email when it puts out news.
Follow Little Green Pharma